ARCHIVES

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

This article is from The Cancer Letter archive.

Vol. 11 No. 14 | April 5, 1985

Download PDF Visit The Full Archive

Related Articles

NCI Awards $10 Million To States for Cervix Screening

September 27, 1974

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

November 26, 2010

Rosenberg’s Gene Transfer Protocol Approved By NIH Advisory Group

October 7, 1988

Conversation with The Cancer Letter: IU’s Loehrer Discusses “Business Decision” To Close Bloomington Proton Beam Center

October 17, 2014

Feds Set Guidelines For Pharma To Help Patients With Cost Of Drugs, While Steering Clear Of Anti-Kickback Law.

April 28, 2006

Kimes Calls Headline On DRG ‘Exaggerated Negativity’ In Letter

April 5, 1991